Sakar Healthcare Ltd · NSE:SAKAR
Sakar Healthcare — Investor Presentation (October 2022)
26 slides from Sakar Healthcare's investor presentation, Oct 8, 2022
Slide 1: NSE Regulation 30 filing cover letter
,.:- Sakar Certified ISO 9001 : 2015 by Healthcare Limited Corporate Office: 406, Silver Oaks Comm. Complex, Opp. Arun Society, Paldi, Ahmedabad-380 007. Gujarat, India. Phone : 079-26584655 Fax: 079-26588054 CI No.: L24231 GJ2004PLC043861 08-10-2022 E-mail : info@sakarhealthcare.com Web : www.sakar
Slide 2: Investor Presentation October 2022
Investor Presentation October 2022
Slide 3: Contents
Contents 03 Sakar Healthcare in a Nutshell 05 Business and Operational Overview 16 Next Phase of Growth in Oncology 22 Key Strengths 24 Pharma Industry Overview 27 Financial Performance Sakar is at crux of next phase of growth, prepared to enter the niche segment of Oncology to cater to Mr. Sanjay S
Slide 4: Sakar Healthcare in a Nutshell
Sakar Healthcare in a Nutshell Indian pharmaceutical manufacturing company since 2004 Established by first generation Sakar manufactures and markets 175 entrepreneur Mr. Sanjay Shah in products, with 292 Registrations 2004 in Changodar, Gujarat, India. under its own name covering more Started with m
Slide 5: Sakar Healthcare in a Nutshell
Sakar Healthcare in a Nutshell Key financial numbers FY22 ICRA BBB/A3+ 292+ 12,823 25% Credit Rating Registered Brands Revenue from Operations CAGR%* (In ₹ Lakh) 450+ 24+ Workforce Therapeutic Areas 2,940 22.9% 24% EBIDTA EBIDTA(%) CAGR%* 60+ 64.5+ Countries Present Promoter Holding 1,501 11.5% 36%
Slide 6: Business and Operational Overview
Business and Operational Overview Business Model Therapeutic Segments Formulation Segmentation Marquee Customers Global Footprint State of Art Manufacturing Facility Leadership and Management 01
Slide 7: Transformation of Business Model
Transformation of Business Model Business Vertical Contribution 18% 5% 29% 22% 53% 73% FY18 FY22 CDMO / CMO CDMO / CMO Own Brand Export Own Brand Export Loan Licensing Loan Licensing CDMO: Operates as a Contract Development & Own Brand Export: Exports constitute of Sakar's Loan Licensing: Involves n
Slide 8: Transformation of Business Model
Transformation of Business Model Revenue from each Business Segment (In ₹Lakh) 9,368 CDMO Over the years, the growth has Export come from developing, Loan Licensing 25% manufacturing & marketing Export 6,925 CAGR formulations under Sakar's own Registered Brands primarily to 5,710 APAC, Latin America
Slide 9: Exposure to several Therapeutic Segments
Exposure to several Therapeutic Segments Width of Therapeutic Segments Top 5 Therapeutic Anti-infective 1 7 Anticoagulant Antipsychotic 13 19 Oxytocic segments are Proton pump Inhibitors, Antibiotic, Analgesic, Anti-depressant Proton Pump Anti Coagulant, Anti Analgesic 2 8 Antiematic 14 20 Inhibitor
Slide 10: Formulation Segmentation
Formulation Segmentation 57% 25% Top 10 Contributed by Injectable group Contributed by Oral Solid Dosage (OSDs) Molecules contribute nearly +45% of the export sales Oral Liquid Key Molecules: The liquid form is the most acceptable dosage form across age groups. It is -Metronidazole (Antibiotic) norm
Slide 11: Formulation Segmentation
Formulation Segmentation Oral Solid (Tablet/Capsule/Dry Syrup) Cephalosporin Key Molecules: Cephalosporins are antibiotics used to treat a wide variety of bacterial infections, -Cefuroxime (Antibiotic) such as respiratory tract infections, skin infections and urinary tract infections. This -Cefpodox
Slide 12: Value derived from each Formulation Segments
Value derived from each Formulation Segments Oral Liquid (In ₹ Lakh) Liquid Injections The products manufactured have application (Vials & Ampoules) (In ₹ Lakh) across wide range of therapeutic segments, in addition Sakar can cater to the customers present across regions which ensures a sustainable
Slide 13: Servicing Multinational Marquee Customers (CDMO / CMO)
Servicing Multinational Marquee Customers (CDMO / CMO) Esteemed customers in CDMO Belief, trust and support of customers Most of these companies ranked amongst top 20 in Indian Pharmaceutical industry and trust Sakar for manufacturing their brands over the years. 16 15 15 Domestically, the company d
Slide 14: Continuously expanding Global Footprint
Continuously expanding Global Footprint In the year 2008, Sakar began Sakar's presence in 60 countries on global map exports with African region; ever since every five years expanded to different regions. Very recently began exports to Europe. Regulatory approvals received from national drug authori
Slide 15: State of the Art Manufacturing Facility
State of the Art Manufacturing Facility Plant Capacity Utilization Built up area Annual capacity Capacity Utilization Changodar, Ahmedabad, Gujarat, Block Facility (Sq Meters) (Single shift) (FY22) India Block 1 Oral Liquid Syrup & Suspension 2,266 80,64,000 57% Manufacturing facility started since
Slide 16: Leadership and Management
The Force behind Sakar's Growth Leadership and Management Ms. Rita Shah Mr. Shailesh Patel Whole Time Director Independent Director Mr. Sanjay Mr. Aarsh ▪ BSc from Gujarat University ▪ Electrical Engineering Shah Shah ▪ Look after the following departments: ▪ Experience of more than 28 years in Chai
Slide 17: Next Phase of Growth - Oncology
Next Phase of Growth- Oncology Greenfield Integrated Oncology Unit Oncology Business Model World Class Facility that supports Sustainability- Green Chemistry 02 Global Oncology Scenario Rationale for Diversifying into Oncology
Slide 18: Greenfield Integrated Oncology Unit
Project Cost Greenfield Integrated Oncology Unit ₹194 * crore Started Operations in Sept.2021 Debt Funding Sanctioned Research-driven API-Integrated Finished Dosage Formulation Plant The standalone unit covers are of 39,121 m2 functioning with - ₹95 crore through Bank Loans Equity Funding Cobra inve
Slide 19: Oncology Business Model
Oncology Business Model Sakar’s Positioning in Oncology Sakar is positioned as a PREMIUM CDMO to partner: o Research & Product development o Scale up pilot/commercial batches Sakar forayed into a different product line by o API EXPORT of Sakar brands to overseas markets / setting-up greenfield manuf
Slide 20: World Class Facility that supports Sustainability- Green Chemistry
World Class Facility that supports Sustainability- Green Chemistry Modern machinery and equipment’s Green Chemistry 1. Vapourtec R Series System, UK 12 principles 2. 3. 4. Glass Line Reactors from De-Dietrich, Italy OSD Containment Granulation and Compression Line, GEA, Belgium Glatt-Autocoater, Ger
Slide 21: Global Oncology Scenario
Global Oncology Scenario Oncology Market Product Sales, 2019 Number of phase I to regulatory submission oncology ($ billion) ($ billion) pipeline products by company segment, 2011-2021 11.1 11.1 2,197 2,169 522 1,845 8.0 1,577 7.1 6.5 1,342 6.1 5.7 1,131 10.2% 271 1,003 901 911 872 870 CAGR Keytruda
Slide 22: Rationale for Diversifying into Oncology
Rationale for Diversifying into Oncology Presence of limited players in India for both Oncology being margin accretive supported by strong API & finished formulations in Oncology due growth drivers across geographies. to high entry barriers thereby ensuring healthy competition. Sakar’s objective w
Slide 23: Key Strengths
Key Strengths Diversified Product Profile, Geographies, Customers and Therapeutic Areas along with multi-end user industry. Entry into the Regulated Markets of Europe, APAC will provide growth impetus Product Pipeline under Registration 200+ An end-to-end solution provider with Vertically Integrated
Slide 24: Demonstrated business growth by diversifying into high value Product Mix
Demonstrated business growth by diversifying into high value Product Mix, across Geographies REVENUE FROM OPERATIONS1 (IN ₹ LAKH) PROFITABILITY1 (IN ₹ Lakh) EBITDA & EBITDA Margin PAT & PAT Margin 217 23% 25% 24% 24% 23% 10% 14% 17% 22% 118 202 68 53 25% 24% 36% 5,308 6,825 8,298 9,474 12,823 1,233
Slide 25: Disclaimer
Disclaimer Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's results may b
Slide 26: Thank You
Thank You October 2022 SAKAR HEALTHCARE LIMITED INVESTOR RELATIONS AT Registered Office Sakar Healthcare Block No. 10-13, Village: Changodar, Sarkhej-Bavla Highway, Bikramjit Ghosh Taluka: Sanand, Ahmedabad- 382 213 bikramjit@sakarhealthcare.com NSE: SAKAR ISIN: INE732S01012 Krishna Patel, Advait Bh
Sakar Healthcare — Investor Presentation (October 2022) on 6ix